Q1 2026 Hansa Biopharma AB Earnings Call Transcript
Key Points
- Hansa Biopharma AB (HNSBF) raised $30 million in a convertible note, significantly extending its financial runway.
- The company successfully paid down $15 million of NovaCrest debt, with no further payments due until mid-2027.
- Hansa Biopharma AB's abstract for the CONFIDUS study was accepted for oral presentation at the American Transplant Congress in June.
- The company initiated a BLA review with the FDA, indicating progress towards U.S. market entry.
- Positive changes in reimbursement pathways in Spain and Germany are expected to drive future sales growth.
- Q1 2026 revenue decreased by 48% compared to Q1 2025, reflecting volatility in the organ allocation market.
- SG&A expenses increased by $29.6 million SEC compared to Q1 2025, driven by non-cash LTIP expenses and fees associated with securing the convertible note.
- The company experienced a decrease in R&D expenses due to the wind-down of clinical trial activities and restructuring actions.
- Headcount decreased from 138 in Q1 2025 to 122 in Q1 2026, indicating potential operational challenges.
- The company did not provide detailed guidance for 2026, creating uncertainty about future performance.
Good day and welcome to the Hansa Biopharma First Quarter 2026 Earnings Results Conference Call.
All participants will be in listen-only mode.
Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.
After today's presentation, there will be an opportunity to ask questions.
To ask a question, you may press star then one on a touchtone telephone.
To withdraw your question, please press star then two.
Please note, this event is being recorded.
I would now like to turn the conference over to Hansa Biopharma CEO Renee Aguiar-Lukander.
Please go ahead.
©- -
Thank you very much. Good afternoon. Good morning, everybody, and welcome to the Hansa Biopharma Conference Call to review the Q1 results for 2026.
I'm Renee Aguirre-Lukander, CEO for Hansa Biopharma. And joining me today is Evan Ballantine, Chief Financial Officer Richard
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
